The CCL1 (Chemokine (C-C motif) ligand 1) antibody is a tool used to study the CCL1 protein, a small cytokine belonging to the CC chemokine family. CCL1. encoded by the *CCL1* gene, binds specifically to the CCR8 receptor, which is predominantly expressed on immune cells like Th2 cells, regulatory T cells (Tregs), and certain dendritic cells. This chemokine-receptor pair plays a role in immune regulation, inflammation, and cell migration. CCL1 is implicated in Th2-mediated immune responses, including allergic inflammation, asthma, and autoimmune diseases. It also contributes to tumor microenvironment modulation by recruiting immunosuppressive Tregs, aiding cancer immune evasion.
CCL1 antibodies are critical in both research and therapeutic contexts. As research tools, they enable detection and quantification of CCL1 in tissues or fluids via techniques like ELISA, Western blot, or immunohistochemistry. Therapeutically, neutralizing anti-CCL1 antibodies are explored for blocking CCL1-CCR8 signaling to suppress pathological immune responses. Preclinical studies suggest their potential in reducing inflammation in autoimmune models or inhibiting tumor progression by disrupting Treg infiltration. However, clinical applications remain under investigation, with challenges including optimizing specificity and minimizing off-target effects. Overall, CCL1 antibodies serve as valuable reagents for unraveling immune pathways and developing targeted therapies.